Curran Simpson | BiotechTV

top of page

STIFEL 2026: REGENXBIO will have its pivotal studies for wet AMD read out before the end of the year - combined, they are the largest study of a gene therapy ever

CEO Curran Simpson sets the table for the readouts and describes what he believes they need to show in order to succeed. Plus, updates on the DMD program and RGX-121. Coverage brought to you by

Company News

1 hour ago

The early part of 2026 is going to be a key time for REGENXBIO's gene therapies, with an FDA decision date scheduled for Hunter's Syndrome and a pivotal trial readout in DMD

CEO Curran Simpson describes REGENXBIO's expertise in AAV, and walks us through the company's programs. Coverage brought to you by

Company News

Nov 11, 2025

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more

bottom of page

STIFEL 2026: REGENXBIO will have its pivotal studies for wet AMD read out before the end of the year - combined, they are the largest study of a gene therapy ever

The early part of 2026 is going to be a key time for REGENXBIO's gene therapies, with an FDA decision date scheduled for Hunter's Syndrome and a pivotal trial readout in DMD

Follow BiotechTV

Sponsors

Sponsor Spotlight